Ronald W. Lennox, D.Phil.

Ron is a graduate of the University of Glasgow, Oxford University and the Wharton School of the University of Pennsylvania. He has carried out basic biomedical research at the European Molecular Biology Laboratory in Heidelberg, where he was a European Exchange Fellow of the Royal Society of London, at Johns Hopkins University, Baltimore and at the Fox Chase Cancer Center, Philadelphia.

Prior to joining CHL Medical Partners in 1997, Ron was a general partner at Hancock Venture Partners (now HarbourVest Partners) where he invested in sixteen healthcare companies, eleven of which have become public companies.

Ron has served on the boards of seventeen companies including General Surgical Innovations, Inc., (acquired by Tyco International Corp.), GeneOhm Sciences, Inc. (acquired by Becton Dickinson), and Protometrix, Inc., (acquired by Invitrogen Corp.). He was founding CEO of Protometrix, Inc. as well as CGI Pharmaceuticals, Inc. and was formerly Chairman of the Board of Amicus Therapeutics, Inc. Ron currently serves as the Chairman of the Board of OpGen, Inc. and on the boards of BIKAM Pharmaceuticals, Inc., BioRelix, Inc. and POINT Biomedical Corp.

Ron can be reached at rlennox@chlmedical.com.